RxDoctor Payments DataLook up a doctor →

Gina D Amato, MD

Hematology & Oncology · Atlanta, GANPI 1750312195

Payments from drug & device makers

$1,860,826in general payments, 2019–2025

Across 352 payments — averaging $5286.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Deciphera Pharmaceuticals Inc.$1.2M
  • Pfizer$207K
  • Sumitomo Pharma America, Inc.$170K
  • Springworks Therapeutics, Inc.$123K
  • Caris MPI, Inc.$86K
  • Incyte Corporation$16K
  • plus $39K from 18 others

What the payments were for

  • Consulting fees$32,48034%
  • Speaking & faculty fees$53,88856%
  • Travel & lodging$5,7126%
  • Food & beverage$4,5735%
  • Education$850%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,860,826 in reported general payments places this provider in the 90th percentile of 370 hematology & oncology providers in Georgia.

See all hematology & oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$35,559
Medicare patients
86
Services billed
382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Pazopanib Hcl25$306,316
TagrissoOsimertinib Mesylate12$202,825
EliquisApixaban14$8,937
Imatinib Mesylate15$1,373
Asa-Butalb-Caffeine-CodeineCodeine/Butalbital/Asa/Caffein13$946
Oxycodone Hcl52$824
Pantoprazole Sodium36$446
Ondansetron Hcl14$224
Ondansetron OdtOndansetron17$220
Gabapentin21$209
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine20$194
Prochlorperazine Maleate17$172
Temazepam17$119
Tramadol Hcl12$84
Lorazepam13$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$11$202,82512 claims
PfizerEliquis$207,058$8,93714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 370 hematology & oncology providers in Georgia.

Other hematology & oncology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →